Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226838 | 1.00 | DGAT1 (0.64) | DGAT1RAB9APOLBHTTLMNA | |
| SCHEMBL4226842 | 1.00 | DGAT1 (0.64) | DGAT1RAB9APOLBHTTLMNA | |
| SCHEMBL4886387 | 0.89 | DGAT1 (0.81) | DGAT1RAB9APOLBHTTLMNA | |
| SCHEMBL4227459 | 0.87 | DGAT1 (0.60) | DGAT1RAB9A | |
| SCHEMBL4227457 | 0.87 | DGAT1 (0.60) | DGAT1RAB9A | |
| SCHEMBL4227463 | 0.87 | DGAT1 (0.60) | DGAT1RAB9A | |
| SCHEMBL13752788 | 0.86 | DGAT1 (0.69) | DGAT1RAB9ALMNA | |
| SCHEMBL4741482 | 0.84 | POLB (0.59) | DGAT1RAB9APOLBHTT | |
| SCHEMBL11531095 | 0.84 | POLB (0.59) | DGAT1RAB9APOLBHTT | |
| SCHEMBL4741046 | 0.84 | POLB (0.59) | DGAT1RAB9APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | DGAT1 34/4885RAB9A 2066/4885POLB 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.